CompletedPHASE2, PHASE3NCT00770393
Laryngeal Preservation in Pyriform Sinus Carcinoma
Studying Squamous cell carcinoma of the larynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
- Principal Investigator
- Jean-Michel PRADES, PrCHU de SAINT-ETIENNE
- Intervention
- induction chemotherapy(procedure)
- Enrollment
- 71 target
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2002 – 2007
Study locations (7)
- CALLOC'H, Aix-les-Bains, France
- LITAS, Le Puy, France
- PIGNAT, Lyon, France
- MAYAUD, Montbrison, France
- Crampette, Montpellier, France
- Lallemant, Nîmes, France
- LACHEB, Roanne, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00770393 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the larynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07209189Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNANCT06915454High-Resolution PET-CT Imaging for Surgical Margin VisualizationVanderbilt-Ingram Cancer Center
- RECRUITINGPHASE2NCT06831149Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal ReconstructionMatthew Spector
- ACTIVE NOT RECRUITINGPHASE1NCT05540899Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck CancerAmerican College of Radiology
- RECRUITINGPHASE2NCT06039631Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal CancerFudan University
- ACTIVE NOT RECRUITINGPHASE2NCT04030455Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT03114462Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal CancerM.D. Anderson Cancer Center